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Calcineurin phosphatase plays a crucial role in T cell acti-
vation. Dephosphorylation of the nuclear factors of activated
T cells (NFATs) by calcineurin is essential for activating cyto-
kine gene expression and, consequently, the immune
response. Current immunosuppressive protocols are based
mainly on calcineurin inhibitors, cyclosporine A and FK506.
Unfortunately, these drugs are associated with severe side
effects. Therefore, immunosuppressive agents with higher
selectivity and lower toxicity must be identified. The immu-
nosuppressive role of the family of proteins regulators of cal-
cineurin (RCAN, formerly known as DSCR1) which regulate
the calcineurin-NFAT signaling pathway, has been described
recently. Here, we identify and characterize the minimal
RCAN sequence responsible for the inhibition of calcineurin-
NFAT signaling in vivo. The RCAN-derived peptide spanning
this sequence binds to calcineurin with high affinity. This
interaction is competed by a peptide spanning the NFAT
PXIXIT sequence, which binds to calcineurin and facilitates
NFAT dephosphorylation and activation. Interestingly, the
RCAN-derived peptide does not inhibit general calcineurin
phosphatase activity, which suggests that it may have a spe-
cific immunosuppressive effect on the calcineurin-NFAT sig-
naling pathway. As such, the RCAN-derived peptide could
either be considered a highly selective immunosuppressive
compound by itself or be used as a new tool for identifying
innovative immunosuppressive agents. We developed a low
throughput assay, based on the RCAN1-calcineurin interac-
tion, which identifies dipyridamole as an efficient in vivo
inhibitor of the calcineurin-NFAT pathway that does not
affect calcineurin phosphatase activity.
Calcineurin (Cn)3 is a calcium/calmodulin-dependent ser-
ine/threonine protein phosphatase and a key enzyme in many
cellular processes, such as T cell activation (1). Activated Cn
dephosphorylatesmany substrates, including the nuclear factor
of activated T cells (NFAT) 1–4 transcription factors, thereby
inducing their translocation to the cell nucleus. Nuclear NFAT
is a key component of the cytokine gene expression stimulation
that triggers T cell activation (2). Cn-induced NFAT dephos-
phorylation is regulated by a Cn-NFAT protein-protein inter-
action that involves the NFAT PXIXIT motif, which is crucial
for NFAT activation and signaling (3).
Current immunosuppressive protocols in transplantation
therapies and in the treatment of autoimmune diseases include
the administration of cyclosporine A (CsA) or FK506. These
drugs are potent inhibitors of Cn phosphatase activity (4), and
their continued administration has been associated with severe
side effects. The binding of these drugs to intracellular immu-
nophilin receptors, before the interaction with calcineurin,
induces complete suppression of Cn phosphatase activity (5).
Therefore, a deeper characterization of the molecular mecha-
nisms that govern the interaction between endogenous Cn reg-
ulators and Cn in T cell activation would provide useful infor-
mation for the development of novel immunosuppressive
drugs.
Several endogenous Cn inhibitors have been identified in the
literature (6), including the protein family of regulators of Cn
(RCAN, previously known as calcipressins or DSCR1) (7),
which interact physically with Cn and modulate its phospha-
tase activity (8–11). In humans, this family has three members:
RCAN1, RCAN2, and RCAN3. RCAN1 has two different and
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independent Cn-interactingmotifs: CIC (Cn inhibitor of Calci-
pressin) and PXIXXT. In contrast, the interaction between
RCAN3 and Cn appears to be driven solely by the CIC motif.
Although RCAN proteins can contain both of these Cn-
binding sites, only the RCAN CIC motif (consensus se-
quence in mammals is LGPGEKYELHA(G/A)T(D/E)(S/
T)TPSVVV HVC(E/D)S) is responsible for inhibiting Cn-
NFAT-dependent signaling in human T cells and, as a result,
T cell activation (12, 13).
In the present study, we characterized a minimal RCAN-
derived sequence (part of the RCAN CIC motif) that retains
the ability to inhibit Cn-NFAT signaling in vivo. The pep-
tides spanning this sequence, RCAN1198–218 from RCAN1
and RCAN3183–203 from RCAN3, were used to conduct a
detailed analysis of the RCAN-Cn-bindingmechanism. In vitro,
these RCAN-derived peptides bind to Cnwith high affinity and
selectively inhibit the interaction of CnwithNFAT.Our results
also suggest that the RCAN-derived peptides impede Cn inter-
action with the NFAT PXIXIT motif but not with the NFAT
LXVPmotif. Interestingly, the RCAN-derived peptides charac-
terized here are specific inhibitors of the Cn-NFAT signaling
pathway but do not inhibit general Cn phosphatase activity in
vitro. Consequently, these peptides could have a favorable pro-
file for immunosuppressive therapy. We hypothesized that
these peptides could serve as valuable pharmacological tools
for identifying new immunosuppressant compounds. By
screening chemical and peptide libraries, we identified dipyri-
damole to be a regulator of the RCAN-Cn interaction that
inhibits the Cn-NFAT signaling pathway in vivo.
EXPERIMENTAL PROCEDURES
Plasmid Construct—Overlapping EGFPRCAN fusion pro-
teins for RCAN1-1 (NCBI accession number AAP96743) and
RCAN3-2 (NCBI accession number AF176116) were designed
and expressed using standard techniques (12). All DNA
sequences were confirmed by DNA sequencing. The pNFAT1-
EYFP plasmid construct was described previously (12). The
pFLAG-NFAT1 (14), human pGEX-6P-1-CnA (amino acids
2–347) (15) and 3XNFAT-luc (16) plasmid constructs were
kindly provided byDr. Gerald Crabtree, Dr. PatrickHogan, and
Dr. Jose´ Aramburu, respectively.
Peptides and Reagents—The peptides RCAN1198–218, KYEL-
HAATDTTPSVVVHVCES; RCAN3183–203, KYELHAGTEST-
PSVVVHVCES; scrambled RCAN1, SAVTHKLESVDPATVY-
CETHV; unrelated peptide, RGKWTYNGYTIEGR; PXIXIT
(motif sequence from NFAT1), ASGLSPRIEITPSHEL; LXVP
(motif sequence from NFAT2), DQYLAVPQHPYQWAK;
mutLXVP, DQYAAAAQHPYQWAK; and phosphorylated RII
peptide, DLDVPIPGRFDRRV-phosphorylatedS-VAAE were
synthesized as acetylated N-terminal and C-terminal amides
using standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chem-
istry on a 433A peptide synthesizer (Applied Biosystems). Sim-
ilar procedures were used to synthesize the N-terminal car-
boxyfluorescein derivatives. Fully deprotected cleaved peptides
were precipitated in cold t-butyl methyl ether, centrifuged, dis-
solved in acetic acid, lyophilized, and purified by reversed
phase-high pressure liquid chromatography (17).MALDI-TOF
mass spectrometrywas used to confirmpeptide identity. FK506
was kindly provided by Fujisawa. Dipyridamole and FKBP12
were purchased from Sigma-Aldrich. Pyrimidopyrimidine was
synthesized at IIQAB (CSIC, Barcelona, Spain).
In Vivo Cellular Assays—COS-7 and U-2 OS cells were tran-
siently transfected with pFLAG-NFAT1 or pNFAT1-EYFP
and different EGFPRCANplasmids to analyze the inhibition of
NFAT nuclear import. HEK 293T cells were transiently trans-
fected with EGFPRCAN1 fusion proteins to analyze their
interaction with endogenous Cn in co-immunoprecipitation
assays. Jurkat cells were electroporated with different EGFP
RCANplasmids and the 3xNFAT-luciferase reporter to analyze
NFAT activity. Endogenous cytokine NFAT-dependent gene
expression of Jurkat cells, either untreated or treated with
dipyridamole, was analyzed by reverse transcription-PCR. All
protocols were performed as described previously (12, 13) with
some modifications, as indicated in the supplemental data.
Fluorescence Polarization Measurement and Library
Screening—Binding and competition assays were performed on
aWallac VICTOR2 1420 multilabel high throughput screening
counter (PerkinElmer Life Sciences). For a detailed description
of the assay, see the supplemental data. The truncated human
CnA-(2–347) protein (hereafter referred to as CnA), which
contains the catalytic domain and the linker region (see supple-
mental Fig. 2A for a schematic representation), was used to
characterize protein-peptide interactions due to its proven
ability to bindNFAT (18, 19). The PrestwickChemical Library
was initially screened at 100 M, and compounds promoting a
45% displacement of the RCAN1198–218-CnA interaction
were evaluated in dose-dependent assays.
CalcineurinPhosphataseActivity—Cnphosphatase activitywas
analyzed using the calcineurin cellular assay kit PLUS (BIOMOL
International LP) according to the manufacturer’s instructions,
with themodifications noted in the supplemental data.
RESULTS
Identification of theMinimal RCAN Sequence Responsible for
Inhibiting the Cn-NFAT Signaling Pathway in Vivo—Immuno-
supression of theCn-NFAT signaling pathway in vivo byRCAN
proteins is caused by the RCAN CICmotif, which spans amino
acids 191–218 for RCAN1 and 178–203 for RCAN3 (12, 13). In
this report, we present the minimal RCAN CIC inhibitor con-
sensus sequence, spanning amino acids 198–218 for RCAN1
and 183–203 for RCAN3, that retains this immunosuppres-
sive role (Fig. 1 and supplemental Fig. 1). These RCAN
sequences are directly responsible for inhibiting NFAT
nuclear translocation in calcium-stimulated cells (Fig. 1A,
compare EGFPRCAN1-(2–252) full-length protein and EGFP
RCAN1-(198–218) and EGFPRCAN3-(183–203) proteins
with mock vector, FLAG-NFAT1, red panels). In contrast, a
full-length RCAN1 mutant lacking this specific sequence fails
to inhibit Cn-regulated NFAT nuclear translocation (Fig. 1A,
EGFPRCAN1 (200–219); FLAG-NFAT1, red panel). How-
ever, this RCAN1 mutant retains the ability to bind in vivo to
endogenous Cn (Fig. 1B, IP -CnA, lane 5) due to the presence
of the PXIXXT motif, which is an additional Cn-interacting
motif in RCAN1 (12). Furthermore, both EGFPRCAN1-(198–
218) andEGFPRCAN3-(188–203) fusionproteins inhibitNFAT-
drivenpromoters in a dose-dependentmanner,with activity com-
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parablewith that of the full-lengthproteins (Fig. 1C). These results
suggest that the inhibitory activity of RCAN proteins on the Cn-
NFAT signaling pathway is specifically dependent on theminimal
RCAN inhibitory consensus sequence identified here. On the
strength of these data, we synthesized a series of RCAN-derived
peptides, RCAN1198–218 and RCAN3183–203 (Fig. 1, D and E),
which do not contain the RCAN PXIXXT motif, and analyzed in
vitro the molecular basis of their binding to Cn.
RCAN1198–218 and RCAN3183–203 Peptides Bind to CnAwith
High Affinity—The protein-protein interaction between
RCAN1 and Cn is well established in the literature (8–11).
However, the only biochemical
characterization reported for this
interaction involves Cn and a long
polypeptide spanning the RCAN1-
(196–252) C-terminal amino acids.
This RCAN1 region contains both
the CIC and the PXIXXT Cn-bind-
ingmotifs (20). However, our in vivo
results show that the RCAN
PXIXXT motif is not essential for
exerting a functional inhibitory
effect on the Cn-NFAT signaling
pathway (Fig. 1 and supplemental
Fig. 1). The RCAN1198–218 and
RCAN3183–203 peptides, whose
sequences include part of the RCAN
CIC but not the RCAN PXIXXT
motif (Fig. 1E), were used to obtain a
more detailed characterization of
the Cn-RCAN interaction. Impor-
tantly, this study is the first bio-
chemical analysis of the recently
identified Cn-RCAN3 interaction
(13). We used human CnA and the
carboxyfluorescein (CF)-labeled
RCAN1198–218 and RCAN3183–203
peptides (CF-RCAN1198–218 and
CF-RCAN3183–203, respectively) to
explore the protein-peptide interac-
tions by fluorescence anisotropy
spectroscopy (21). Both the
CF-RCAN1198–218 and the CF-
RCAN3183–203 peptide bind toCnA
(Fig. 2, A and B, respectively) with
apparent dissociation constants (Kd)
in the low physiological micromolar
range (Fig. 2E). The interaction
betweenCnAand theRCAN-derived
peptides was also confirmed qualita-
tively by peptide-protein cross-link-
ing followed by mass spectrometry
(MALDI-TOF) analysis (data not
shown). The specificity of the
CF-RCAN1198–218-CnA interaction
was assessed by conducting competi-
tion experiments with the unlabeled
peptide RCAN1198–218, which com-
peted effectivelywith the interaction, andwith anon-related and a
scrambledpeptide (see “ExperimentalProcedures”), bothofwhich
were unable to compete with the interaction (Fig. 2C). Similar
experiments demonstrated the specificity for the binding of
CF-RCAN3183–203 to CnA (Fig. 2D). As expected, due to the high
amino acid conservation in both RCAN-derived peptides, cross-
competition experiments showedcross-affinity for theCnA-bind-
ing site (Fig. 2E, see corresponding apparent IC50 values), which sug-
gests that both peptides could interact with the sameCnA region. In
conclusion,ourresults showthatbothRCAN-derivedpeptides inter-
act specifically andwith high affinitywithCnA.
FIGURE 1. The RCAN1-(198–218) and RCAN3-(183–203) sequences inhibit Cn-dependent NFAT signal-
ing. A, immunofluorescence microscopy of COS-7 cells transiently co-transfected with pFLAG-NFAT1 and
different pEGFPRCAN1 andpEGFPRCAN3plasmid constructs. Cells were stimulatedwith 1M ionomycin and
10 mM CaCl2. FLAG-NFAT1 (in red) was immunodetected using a secondary antibody conjugated to the Alexa
Fluor 568 fluorochrome, whereas RCAN proteins (in green) were visualized by the presence of EGFP in the
fusion protein. 4,6-Diamidino-2-phenylindole staining (in blue) confirmed cell integrity. B, co-immunoprecipi-
tation (IP) of CnA and RCAN1 proteins in HEK 293T cellular extracts transiently transfected with different
EGFPRCAN1 fusion proteins. Proteins were co-immunoprecipitated using an anti-CnA antibody. Asterisks
correspond to the immunoglobulin heavy chain.WB, Western blotting. C, RCAN proteins inhibit NFAT-driven
gene expression. Jurkat cells (20  106) were transiently co-transfected with 10 g of pEGFPRCAN1,
pEGFPRCAN3 full-length (FL) plasmids, or increasing concentrations (100 ng, 1 g, and 10 g) of
pEGFPRCAN1-(198–218) or pEGFPRCAN3-(183–203), together with 3xNFAT-luc (20 g). Renilla-luc
(pGL4.75(hRluc/CMV), 0.2 g) was used as an internal transfection control. Cells were stimulated with 1 M
ionomycin (Io) and 20 nM phorbol 12-myristate 13-acetate (indicated by P in the figure) for 4 h. Results from
promoter fold activationof the luciferase reporter plasmid (luciferase/Renillaunits) are given as percentages of
NFAT activation. Values from Io  phorbol 12-myristate 13-acetate (IoP)-stimulated cells transfected with
EGFP, 3xNFAT-luc, and Renilla-luc were considered to be 100%NFAT activation. The graph shows themean
S.D. of three independent experiments performed in triplicate.D, RCAN-derived peptide consensus sequence
inmammalian and humanRCAN1198–218 and RCAN3183–203 peptide sequences. E, schematic diagram showing
the Cn-binding RCAN1motifs characterized to date. The light gray box corresponds to the RCAN PXIXXTmotif,
the dark gray box corresponds to the RCAN CIC motif, and the striped box indicates the localization of the
RCAN-derived peptides. N-ter, N-terminal; C-ter, C-terminal.
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The CnA-binding PXIXIT Sequence in NFAT Interferes with
RCAN-CnA Interaction—Previous reports have demonstrated
that two independent NFAT motifs participate in the NFAT-
CnA interaction: the PXIXIT motif, which binds to Cn and
facilitates NFAT dephosphorylation and activation (3), and the
LXVPmotif (22) (see supplemental Fig. 2B for a schematic rep-
resentation). We wanted to determine whether the RCAN-de-
rived peptides could inhibit NFAT dephosphorylation by inter-
feringwith theCn-binding sequencemotifs inNFAT (Fig. 3). In
fact, a peptide derived from the human NFAT1 PXIXIT motif
(called PXIXIT) competed strongly with the interactions
between CnA and the RCAN1198–218 and RCAN3183–203 pep-
tides (Fig. 3,A andB; apparent IC50 values are shown in Fig. 3E).
Similar results (data not shown) were observed when competi-
tion experiments were performed with the previously reported
VIVIT peptide (16), which is a high affinity Cn-binding peptide
optimized from the NFAT PXIXIT natural sequence. In con-
trast, a peptide derived from the NFAT2 LXVP motif (called
LXVP) only showed competition at high peptide concentra-
tions (Fig. 3, C and D). An analog peptide in which alanine
residues replace the key amino acids of the LXVP peptide (13)
(called mutLXVP, see “Experimental Procedures”) showed no
competition (Fig. 3, C and D; apparent IC50 values are summa-
rized in Fig. 3E). As a control, we confirmed that the NFAT
peptides PXIXIT and LXVP, but not mutLXVP, were able to
compete with the NFAT PXIXIT-CnA interaction in vitro,
which suggests that these peptides bind effectively toCnA (data
not shown). Overall, these results suggest that RCAN proteins
disrupt NFAT binding to CnA. This is caused by the interfer-
ence between either RCAN1198–218 or RCAN3183–203 and the
NFAT PXIXIT peptide, which is crucial in the recognition and
dephosphorylation of NFAT by Cn and, by extension, in NFAT
activation (3). Interestingly, it has recently been reported that
the NFAT PXIXIT sequence motif interacts with CnA through
the CnA catalytic domain (amino acids 70–333) (19, 23, 24).
Our competition experiments strongly support the hypothesis
that the RCAN-derived peptides interact withCnA through the
Cn catalytic domain, as described for the NFAT PXIXIT
sequence motif (19, 23).
The RCAN-derived Peptides DoNot Inhibit General Cn Phos-
phatase Activity—The RCAN1 C-terminal region (which
includes the CIC and the PXIXXT sequences that bind Cn) has
been found to inhibit Cn phosphatase activity on the synthetic
substrate p-nitrophenyl phosphate (20, 25). An in vitro enzyme
assay was performed to evaluate the effect of the RCAN-derived
peptides onCnphosphatase activity (Fig. 4A). TheRCAN1198–218
and RCAN3183–203 peptides do not inhibit the enzymatic activ-
ity of Cn toward the phosphorylated RII peptide substrate (Fig.
4A). As a control, the NFAT LXVP peptide (but not the mut-
LXVP) (24) inhibited Cn phosphatase activity in a dose-
dependent manner (Fig. 4A). Furthermore, protein-peptide
cross-linking and mass spectrometry analyses showed that
FIGURE 2. RCAN1198–218 and RCAN3183–203 peptides bindwith high affin-
ity to human CnA. A and B, binding of 30 nM CF-labeled RCAN peptide
CF-RCAN1198–208 and CF-RCAN3183–203, respectively, to increasing amounts
of CnA. Data, given as millipolarization (mP) units, were analyzed with the
GraphPad PRISM 4.0 program and fitted using a non-linear regression
model to a sigmoidal dose-response curve. C and D, RCAN1198–218-CnA and
RCAN3183–203-CnA interactions were established using 30 nM CF-RCAN pep-
tides and 1.5 M CnA and competed with increasing amounts of unlabeled
peptides. A RCAN1198–218 scrambledpeptide and anon-relatedpeptidewere
included as controls. Data were fitted to a one-site competition model.
E, summary of apparent Kd and IC50 values obtained for the RCAN1
198–218 and
RCAN3183–203 peptides in the interaction of CnA.
FIGURE3.TheNFATPXIXITmotif interfereswith thebindingof theRCAN-
derivedpeptides toCnA.AandB, competitionof theRCAN1198–218-CnAand
RCAN3183–203-CnA interactions, respectively, with increasing concentrations
of unlabeled NFAT PXIXIT peptide. mP, millipolarization units. C and D, com-
petition experiments of the RCAN1198–218-CnA and RCAN3183–203-CnA inter-
actions, respectively, in the presence of the unlabeled LXVP ormutLXVP pep-
tides. E, summary of apparent Kd and IC50 values for NFAT PXIXIT, LXVP, and
mutLXVP peptides. N.D. not determined.
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the phosphorylated RII peptide is able to bind CnA under
our experimental conditions (Fig. 4B). Finally, in agreement
with the results shown in Fig. 4A, the phosphorylated RII
peptide does not compete with the RCAN1198–218-CnA or
RCAN3183–203-CnA interactions (Fig. 4C). Taken together,
these results suggest that both RCAN-derived peptides bind to
the catalytic domain of CnA without directly affecting the cat-
alytic activity of Cn. This contrasts with CsA and FK506 immu-
nosuppressant drugs, which totally abrogate general Cn phos-
phatase activity. Therefore, from a therapeutic perspective, the
RCAN1198–218 and RCAN3183–203 peptides could be consid-
erednovel, highly specific compoundswithwhich to define new
specific immunosuppressive drugs.
Dipyridamole Interferes with in Vivo Cn-NFAT Signaling—
Based on the specific immunosuppressive potential of the
RCAN-derived peptides toward the Cn-NFAT signaling path-
way, we screened several chemical libraries to identify mole-
cules capable of disrupting the interaction between CnA and
the RCAN1198–218 peptide. We first screened a hexapeptide-
based library (26, 27) and a diversity-oriented positional scan-
ning library ofN-alkylglycine trimers, both of which had previ-
ously provided lead compounds for different biological assays
(28–31); however, no suitable hit was found.We then screened
the Prestwick Chemical Library, which comprises 880 biolog-
ically activemolecules with high chemical and pharmacological
diversity; dipyridamole was identified as a compound that
competes with CnA for binding to fluorescently labeled
RCAN1198–218 peptide.
Dipyridamole has been found to inhibit tumor necrosis fac-
tor- production in activated human peripheral blood leuko-
cytes (32), but the mechanism responsible for this activity has
not yet been described. Moreover, it is difficult to establish a
molecular characterization of the mechanism by which dipyri-
damole binds to CnA due to the intrinsic fluorescence of the
molecule. To address this problem, we performed a functional
evaluation of the inhibitory effect of dipyridamole on
Cn-NFAT signaling (Fig. 5). First, we analyzed the in vitro effect
of dipyridamole on Cn phosphatase activity. Our results show
that dipyridamole does not inhibit general Cn phosphatase
activity (Fig. 5A), which is also the case of RCAN-derived pep-
tides (Fig. 4A). Next, we performed several experiments to
FIGURE4.TheRCAN-derivedpeptidesdonot inhibit Cnphosphatase activity.A, the in vitrophosphatase activity of Cnon thephosphorylatedRII substrate
was measured in the absence or presence of different peptides (RCAN1198–218, RCAN3183–203, LXVP, and mutLXVP) at concentrations of 10, 100, and 500 M.
Each reactionwas performed in the presence of 40 units of human recombinant Cn (Calbiochem) and at the indicated concentrations of the three peptides for
1 h at 30 °C. The specific activity of Cnwas 2.810units/mgof protein. Thepicomoles of freephosphate releasedduring the reaction timeweremeasured. The
data shown represent the mean S.D. of three independent experiments. B, MALDI-TOF mass spectrometric analysis of CnA (41 kDa) cross-linked with the
phosphorylated RII peptide (2239 Da) indicated by the gray and black spheres, respectively. C, competition of the RCAN1198–218-CnA () and the RCAN3183–
203-CnA (ƒ) interactions with increasing amounts of unlabeled phosphorylated RII (phosphoRII) peptide.
FIGURE 5. Dipyridamole interferes with Cn-NFAT cellular signaling in
vivo. A, the in vitro phosphatase activity of Cn on the phosphorylated RII
substrate was measured in the absence or presence of dipyridamole (10, 50,
and500M). As an inhibitory control, calcineurin activitywasmeasured in the
presenceof 10MFK506 and10MFKBP12. Thepicomoles of freephosphate
released during the reaction were measured, and the data obtained from
three independent experiments was expressed as the mean S.D. B, U-2 OS
cells were transfected with NFAT1EYFP (red) and unstimulated, stimulated
with 2 M Io and 10 mM CaCl2 for 25 min in the presence of vehicle or dipyri-
damole (green; addedpreviously at 50M for 16 h), or inhibitedwith 1MCsA
for 30 min before administration of the stimuli. The images represent three
independent experiments. C, Jurkat cells were transfected with 3xNFAT-luc
and Renilla-luc (pGL4.75(hRluc/CMV)), as an internal transfection control, and
treated 12 h after transfectionwith either 1MCsA, as a control, or increasing
concentrations of either dipyridamole or pyrimidopyrimidine (1, 10, 20, 50,
and 100M) for 3 h at 37 °C and 5%CO2. Cells were then either not treated or
treated with 1 M Io and 20 nM phorbol 12-myristate 13-acetate (P) for 4 h.
Luciferase/Renillaunit results are shownas in Fig. 1C. The values represent the
average of three independent experiments. D, Jurkat cells were treated with
vehicle or dipyridamole at different concentrations, as shown in panel A. The
cells were then left unstimulated (), stimulated with 1 M Io and 20 nM
phorbol 12-myristate 13-acetate for 4 h (IP), or inhibited with 1M CsA for 30
min before administration of the stimuli (CIP). NFAT-dependent gene expres-
sionwas analyzed by semiquantitative reverse transcription-PCR. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) transcription level was used as a
control. IL3, interleukin-3; CSF2, colony stimulating factor 2; TNF-, tumor
necrosis factor-.
An RCAN Peptide That Inhibits Calcineurin-NFAT Signaling
9398 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 14•APRIL 3, 2009
 at IN
ST BIO
M
ED
ICIN
A
 D
E V
A
LEN
CIA
 on M
ay 18, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
determine the in vivo effect of dipyridamole on Cn-NFAT sig-
naling. Dipyridamole inhibits NFAT nuclear translocation in
vivo at 50 M (Fig. 5B). In addition, dipyridamole, but not its
synthetic analog pyrimidopyrimidine, specifically inhibits an
NFAT-driven promoter in a dose-dependent manner (Fig. 5C).
Consequently, cytokine NFAT-dependent transcription is
affected in a dose-dependent manner in human T cells (Fig.
5D). Our in vitro and in vivo experiments demonstrate the
dipyridamole-dependent inhibition of theCn-NFAT signaling
pathway. This inhibitory effect onCn seems to be specific to the
NFAT substrates because dipyridamole does not affect general
Cn phosphatase activity. These data constitute the first exper-
imental identification of a disrupter of the interaction between
Cn and RCAN in vitro that affects Cn-NFAT dependent signal-
ing in vivo.
DISCUSSION
RCAN1198–218 and RCAN3183–203 Are High Affinity CnA-
binding Peptides—We have identified the minimal RCAN
region, RCAN1-(198–218) and RCAN3-(183–203), responsi-
ble for in vivo inhibition of the Cn-NFAT signaling pathway
(Fig. 1 and supplemental Fig. 1). More importantly, biochem-
ical characterization of the interaction between two RCAN-
derived peptides spanning these sequences (RCAN1198–218
and RCAN3183–203) and CnA has revealed that both RCAN-
derived peptides interact with high affinity with CnA through a
region located between amino acids 2 and 347. This region
includes the CnA catalytic domain (residues 70–333) and the
linker region (residues 335–347) (Fig. 2, A and B, and supple-
mental Fig. 2A). These results reinforce previous evidence indi-
cating a putative role of the CnA catalytic domain and linker
region in binding to RCAN1 (10, 11). These regions have also
been implicated in CnA binding to NFAT and other Cn inhib-
itor proteins such as Cabin1 and AKAP79 (5, 33). Taken
together, these data suggest that different Cn endogenous
inhibitorsmay interact withCn through closely related regions.
The NFAT PXIXIT Sequence Interferes with the Interaction
between RCAN-derived Peptides and CnA—The regulatory
mechanism by which Cn binds to NFAT or RCAN proteins is a
matter of speculation due to the presence of different Cn-bind-
ing sites in NFAT (the PXIXIT and LXVPmotif sequences) and
in RCAN (the CIC and PXIXXT motif sequences). RCAN pro-
teins have been found in different cell systems to interfere in
vivo with Cn-NFAT signaling (10, 20, 34). In addition, the
RCAN1-4 protein isoform has been found to compete for Cn
bindingwith theVIVIT peptide, which is a peptide derivative of
the NFAT PXIXIT sequence motif (35). However, a detailed
identification of the RCAN sequence responsible for these
molecular events was not carried out. The competition experi-
ments presented here describe for the first time the existence of
direct competition between RCAN-derived peptides and the
NFAT1 PXIXIT peptide for binding to CnA. Therefore, these
results could potentially be extrapolated to full-length proteins.
The functional consequence of this competition is to prevent
NFAT activation and, subsequently, T cell activation. Our
results also suggest that the RCAN-derived peptides could bind
to CnA through a region that either partially overlaps or is
proximal towhere theNFATPXIXITmotif binds. However, we
cannot rule out that binding of one peptide (the RCAN-derived
peptides) to any other calcineurin domain could affect the
enzyme conformation and binding to the other peptide (NFAT
PXIXIT peptide). We hypothesized that both RCAN peptides
would interact within the catalytic domain of CnA through a
region located outside theCnAactive site and probablywithout
direct participation of the linker region. This hypothesis is fur-
ther supported by the recent structural characterization of the
protein-protein surface interaction, defined by binding of the
VIVIT peptide (16) to CnA (19, 23). The surface is defined by
direct interaction of an exposed short -strand of CnA and by
the -sheet conformation adopted by the VIVIT peptide. The
structure of the complex did not reveal any interactions
between the CnA linker region and the peptide. Finally, taking
into consideration our data here presented (Fig. 3E), we cannot
discard that the NFAT LXVP peptide could also play some role
in the competition of the RCAN-derived peptides interaction
with CnA. Nevertheless, this competitive effect would be
expected to be in a lesser extent than the one mediated by the
NFAT PXIXIT peptide. Further experiments would need to be
addressed to clarify this point.
The RCAN-derived Peptides DoNot Inhibit General Cn Phos-
phatase Activity—One of themain findings of the present study
is that the RCAN-derived peptides do not inhibit Cn phospha-
tase activity toward phosphorylated RII peptide substrate (Fig.
4A). In addition, the LXVP peptide, which significantly blocks
RII dephosphorylation by Cn (24), only competed with the
RCAN-derived peptides for binding to CnA at high concentra-
tions (Fig. 3, C and D). Neither CsA-cyclophilin A nor FK506-
FKBP12 complexes competed with the CnA-RCAN-derived
peptide interactions, although both interact with CnA under
our experimental conditions (data not shown). Overall, these
results suggest that the interaction between RCAN-derived
peptides and CnA does not involve the direct participation of
the CnA active site. These data differ from those of previous
reports, in which the complete C-terminal region of RCAN1
was shown to be a competitive inhibitor of Cn in a phosphatase
activity assay using the p-nitrophenyl phosphate or synthetic
RII peptide as substrates (20, 25). Here, we used well defined
C-terminal RCAN-derived peptides, which do not include the
RCAN PXIXXT motif and enabled fine characterization of the
RCANmotif that inhibits Cn-NFAT signaling in vivo. Interest-
ingly, the RCAN-derived peptides do not abolish Cn phospha-
tase activity in vitro, unlike CsA or FK506. This suggests that
the Cn inhibitory effect of these peptides might be specific to
NFAT dephosphorylation.
RCAN1198–218 and RCAN3183–203 Are Potential Immunosup-
pressive Peptides That Could Be Used as Screening Tools—
Our data suggest a potentialmodel for themechanismbywhich
the RCAN-derived peptides bind to Cn via its catalytic domain,
through a region located outside the active site. In this position,
the RCAN-derived peptides would not inhibit Cn phosphatase
activity but would selectively interfere with the Cn-binding
PXIXIT motif of NFAT. This effect would, in turn, prevent
NFAT dephosphorylation and, as a result, T cell activation.
RCAN-derived peptidesmight also interfere withCnA-binding
sites for other proteins, which could be located close to the
RCAN-binding site, although this hypothesis demands further
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examination. The RCAN-derived peptides identified here
could constitute novel, selective immunosuppressive lead can-
didates and potential therapeutic alternatives to CsA or FK506,
presumably with fewer side effects (16, 36). However, given the
multiple effects of Cn-dependent NFAT activation on cell reg-
ulation, we cannot rule out the possibility that NFAT inhibitors
that do not affect the Cn active site could also have some toxic
side effects. Specific experimentsmust be performed to address
this question. Nevertheless, these RCAN-derived peptides
could be used to identify new, more specific immunosuppres-
sant drugs through the exploration of alternative Cn-binding
sites that may inhibit the Ca2-Cn-NFAT signaling pathway
(15, 37, 38). Therefore, the binding site in CnA for the RCAN-
derived peptides may be a new target site for the development
of such drugs. Based on this hypothesis, we screened chemical
libraries under restrictive assay conditions. By imposing
screening constraints, we limited the putative hits to molecules
that could compete with CF-RCAN1198–218, bind to its binding
site in CnA, and inhibit the protein-protein interaction that
produces the active CnA-NFAT complex. The screening iden-
tified dipyridamole to be a hit compound for the development
of this new class of inhibitors. It competed efficiently with
CF-RCAN1198–218 in in vitro CnA binding assays. Dipyri-
damole also inhibited Cn-dependent NFAT nuclear transloca-
tion (Fig. 5B), NFAT activity (Fig. 5C), and NFAT-dependent
cytokine gene expression in human T cells (Fig. 5D), without
affecting general phosphatase activity (Fig. 5A). Although
dipyridamole is widely used in clinical practice as an antiplate-
let agent to prevent recurrence of ischemic stroke (39), in
recent years, it has also been suggested that this drug could have
an immunomodulatory effect in vivo (32, 40). However, the
molecular mechanism responsible for this novel role remains
unknown. Interestingly, our results suggest that dipyridamole
may play a role in immunosuppression and that this role could
be regulated through the inhibition of the Cn-NFAT signaling
pathway.
In summary, we have gained crucial insights into the under-
lying mechanism of Cn binding to RCAN1 and to RCAN3.
When overexpressed in cells, the amino acid sequences of
RCAN1-(198–218) and RCAN3-(183–203) inhibit Cn-NFAT
signaling, thereby preventing activation of NFAT without
affecting Cn phosphatase activity. We have also defined two
novel sequences, the RCAN1198–218 and RCAN3183–203 peptides,
that could be valuable pharmacological tools. Once the current
difficulties of intracellular peptide delivery have been overcome,
these synthetic peptides could also prove beneficial in immuno-
suppressive therapy. Using these peptides as screening tools, we
identifieddipyridamole tobe ahit compound for thedevelopment
of new immunosuppressantmolecules, providing advantages over
the currently used drugs CsA and FK506.
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